NCT02621177View on ClinicalTrials.gov

Study of Egg-derived Influenza Vaccine and Cell Culture-derived Influenza Vaccine in Healthy Children and Adolescents

PHASE3CompletedINTERVENTIONAL
Enrollment

385

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

March 31, 2014

Study Completion Date

July 31, 2014

Conditions
Influenza, Human
Interventions
BIOLOGICAL

NBP607

For subjects 6 months to 8 years of age, single intramuscular dose for primed subjects, two doses for unprimed subjects. For subjects 9 to 18 years of age, single intramuscular dose (0.25mL/0.5 mL)

BIOLOGICAL

Agrippal S1

For subjects 6 months to 8 years of age, single intramuscular dose for primed subjects, two doses for unprimed subjects. For subjects 9 to 18 years of age, single intramuscular dose (0.25mL/0.5 mL)

All Listed Sponsors
lead

SK Chemicals Co., Ltd.

INDUSTRY

NCT02621177 - Study of Egg-derived Influenza Vaccine and Cell Culture-derived Influenza Vaccine in Healthy Children and Adolescents | Biotech Hunter | Biotech Hunter